

Informazione Regolamentata n. 20106-51	Data/Ora Inizio Diffusione 21 Dicembre 2023 15:24:35	Euronext Star Milan
--	---	---------------------

Societa' : PHARMANUTRA

Identificativo Informazione
Regolamentata : 184725

Nome utilizzatore : Roberto Lacorte

Tipologia : REGEM

Data/Ora Ricezione : 21 Dicembre 2023 15:24:35

Data/Ora Inizio Diffusione : 21 Dicembre 2023 15:24:35

Oggetto : PR Financial Calendar 2024

Testo del comunicato

Vedi allegato

PHARMANUTRA S.P.A.: PUBLICATION OF THE 2024 CORPORATE EVENTS CALENDAR

Pisa, 21st December 2023 - [PharmaNutra S.p.A.](#) (the "**Company**") announces the dates for the approval of the financial results of the Company by the Board of Directors and the Shareholders' Meeting:

Date	Event
March 15 th , 2024	Board of Directors for the approval of the Financial Statements as of 31st December 2023
April 16 th , 2024	Ordinary Shareholders' Meeting for the approval of the Financial Statements as of 31st December 2023
May 13 th , 2024	Board of Directors Meeting for the approval of the Interim Management Statements as of 31st March 2024
September 9 th , 2024	Board of Directors Meeting for the approval of the Half-Yearly Report as of 30th June 2024
November 11 th , 2024	Board of Directors Meeting for the approval of the Interim Management Statements as of 30th September 2024

Any amendments to the above calendar will be notified to the market timely.

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. PharmaNutra is a leader in the production of iron-based nutritional supplements with the SiderAL® brand, where it can claim important Sucrosomial® Technology patents, and is considered one of the top players in the sector of medical devices dedicated to the restoration of joint capacity thanks to the Cetilar® brand, now on the market also with Cetilar® Nutrition, a line of supplements designed for those who practice sport constantly. Over the years the Group - present abroad in 85 countries - has developed precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

PharmaNutra.it

For further information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

investorrelation@pharmanutra.it

Internal Press Office

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com

Fine Comunicato n.20106-51

Numero di Pagine: 4